MedElevator Войти в исследования
← Поиск публикаций

DOI 10.15403/jgld-6501

Медицинская библиотека · Journal of gastrointestinal and liver diseases : JGLD · 2025

A Decade of Bulevirtide Use in Chronic Hepatitis Delta: Real-World Clinical Results.

Rusch Sophia, Stöckert Petra, Schmid Stephan, Schilling Tobias, Müller Martina

СтатьяПеревод в очереди

Аннотация

BACKGROUND AND AIMS: Until recently, the only available treatment option for hepatitis D virus (HDV) was the off-label use of interferon, which is associated with limited efficacy and considerable side effects. The approval of the first HDV-direct antiviral, bulevirtide (BLV), has introduced a targeted therapeutic option for patients with chronic hepatitis delta. We assessed the clinical efficacy of BLV in our HDV patients.

METHODS

We conducted a retrospective analysis of all patients diagnosed with HDV infection in our department over the past 10 years. For statistical analysis, we performed multivariate analysis of variance, MANOVA.

RESULTS

26 patients tested positive for HDV antibodies (17 developed chronic hepatitis delta). Eleven patients received BVD. At treatment initiation, liver cirrhosis was present in three patients in the bulevirtide group (MELD-Na: 9-10; Child-Pugh: 5-7) and in three patients in the no bulevirtide group (MELD-Na: 13-18; Child-Pugh: 5-8). Over 12 months of follow-up, bulevirtide recipients showed reductions in alanine aminotransferase (ALT; mean baseline 88 U/L vs 59 U/L; controls 230 U/L vs 206 U/L; MANOVA between-subject effect: p<0.05), aspartate aminotransferase (AST; 68 U/L vs 56 U/L; controls 208 U/L vs 151 U/L; p<0.05), bilirubin (0.74 mg/dL vs 0.65 mg/dL; controls 1.48 mg/dL vs 1.17 mg/dL; p<0.005), HDV-RNA (1,323,182 copies/mL vs 36,975 copies/mL; controls 416,825 copies/mL vs 17,914,733 copies/mL; p<0.05) a statistically significant time-by-group interaction was found for both Child-Pugh scores (p<0.0001) and MELD-Na scores (p<0.05), indicating improved liver function over time in the BLV group compared to controls. No progression of liver fibrosis was observed.

CONCLUSIONS

Bulevirtide is a safe and effective treatment for chronic hepatitis delta in a real-world clinical setting. These findings support its role as a sustainable therapeutic option for patients with HDV infection.

Для цитирования: Rusch Sophia, Stöckert Petra, Schmid Stephan, Schilling Tobias, Müller Martina. A Decade of Bulevirtide Use in Chronic Hepatitis Delta: Real-World Clinical Results.. Journal of gastrointestinal and liver diseases : JGLD. 2025. DOI: 10.15403/jgld-6501.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.